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Abstract 
Purpose: To evaluate the anti-fibrotic effects of ethanol extract of Rhus javanica Linn. (Anacardiaceae) 
(RJE) in activated hepatic stellate cells (HSCs) as well as explore the underlying mechanisms.  
Methods: The cytotoxic effect of RJE (100, 300 and 500 µg/mL) was analyzed using 3-[4, 5-
dimethylthiazol-2-yl]-2, 5-diphenyl tetrazolium bromide (MTT) assay in Chang liver cells. The mRNA 
expression of collagen type I, alpha 2 (COL1A2), transforming growth factor-beta (TGF-β), α-smooth 
muscle actin (α-SMA) and platelet-derived growth factor (PDGF) were determined using reverse 
transcription-polymerase chain reaction (RT-PCR) in HSCs. Protein expression of collagen and Smad 
were measured by Western blot analysis.  
Results: Treatment with RJE extract at 100, 300 and 500 μg/mL did not show any signs of cytotoxicity 
to Chang liver cells. RJE at 500 μg/mL concentration influenced the morphology, reduced the stretched 
fiber and decreased the number of viable cells in activated HSCs. The increased expressional levels of 
fibrosis mediators such as COL1A2, TGF-β, α-SMA were decreased by RJE (500 μg/mL) pre-treatment. 
Quantification data showed that the increased band intensity of COL1A2 (1.41 ± 0.08), TGF-β (1.23 ± 
0.13), α-SMA (1.71 ± 0.14) were significantly (p < 0.05) reduced to 0.39 ± 0.12, 0.35 ± 0.11 and 0.04 ± 
0.08, respectively upon RJE treatment. However, RJE did not suppress the expression of PDGF gene. 
Mechanistic study revealed that RJE prevented fibrosis in HSCs via regulation of TGF-β and Smad 
signaling pathways.  
Conclusion: The findings show that RJE inhibits fibrosis production in HSCs and can be developed as 
a novel therapy for hepatic fibrosis. This is the first report showing the beneficial effects of R. javanica 
as an anti-fibrotic agent. 
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Liver fibrosis is a common consequence of 
chronic liver injury caused by a variety of 
mechanisms including oxidative damage, viral 
infection, and certain genetic diseases [1]. 
Fibrosis is defined by the excessive 
accumulation of the extracellular matrix (ECM) 
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protein around inflamed or damaged tissue, 
which can lead to permanent scarring, organ 
malfunction including kidney disease, liver 
disease, idiopathic pulmonary fibrosis (IPF) and 
heart failure [2,3].  
 
Liver fibrosis received little attention until the 
1980s, when hepatic stellate cells (HSCs), 
formerly known as lipocytes, Ito cells, or 
perisinusoidal cells, were identified as the main 
collagen-producing cells in the liver [4]. HSCs are 
presently regarded as one of the key cell types 
involved in the progression of liver fibrosis [5]. In 
normal liver, HSCs were described as being in a 
quiescent state. They represent 5 – 8 % of the 
total number of liver cells [6].  
 
The most intriguing aspect of the involvement of 
HSCs in liver fibrogenesis is that they undergo 
phenotypic changes often characterized as 
myofibroblastic activation [7].  The activation of 
HSCs to a proliferative, myofibroblastic 
phenotype plays a key role in hepatic 
fibrogenesis, since these cells are the principal 
cellular source of the excess collagen synthesis 
during hepatic fibrosis [8].  Activated HSCs 
secretes collagen scar for protection which 
underlies the recovery from liver diseases. 
However, if this is not recovered, this proceeds to 
liver fibrosis, liver cirrhosis and liver cancer [8].  
Therefore, the prevention of liver fibrosis has 
great significance in ameliorating chronic liver 
diseases.  
 
Use of herbal and natural products in the 
treatment of liver disorders has a long tradition 
and scientists have focused on certain natural 
products in the treatment of liver fibrosis [9].  In 
the search for novel promising agents from 
natural products for preventing and/or treating 
hepatic fibrosis, Rhus javanica Linn. extract from 
the family Anacardiaceae was evaluated. R. 
javanica, a deciduous arborescent plant, grows 
widely at the foot of mountains and ravines in 
Korea, China and other Asian countries. 
Traditionally, R. javanica fruit has been used as 
anti-diarrheal, anti-tussive, anti-coagulant and 
anti-perspirant. The leaves of R. javanica have 
been used as detoxicant, anti-venom for snake 
bites and are reported to possess 
hepatoprotective and antioxidant properties [10].   
The parasitic cocoon known as “Gallunt” on R. 
javanica tree which contains gallotammin as 
major component, also has effects such as, anti-
diarrhea, hemostasis, anti-biotic, liver protection, 
detoxicant and anti-oxidant [10].  Reports also 
indicate that R. javanica has been widely used to 
treat cancer, dysentery, diarrhea, parasitic and 
bacterial infections in Korea, China, Japan and 
other Asian countries for centuries [11]. 
However, till date no evidence exists regarding 
the anti-fibrotic effects of R. javanica.  
 
In the present investigation we evaluated the 
anti-fibrotic effects of R. javanica extract in an in 
vitro system using hepatic stellate cells (HSCs) 




Plant material  
 
The whole plant material of R. javanica was 
purchased from Plant Extract Bank, Daejeon, 
Korea. The material was authenticated by Dr 
Jong-Bo Kim, a taxonomist at Konkuk University, 
Korea, based on its microscopic and 
macroscopic characters. A voucher specimen 
(No: KKU-RJ13) was deposited at the herbarium 
of Konkuk University, Korea for future reference.  
 
The dried plant material (50 g) was powdered 
and extracted with ethanol using Soxhlet’s 
extraction technique for 3 days. The extract was 
then concentrated under reduced pressure at 45 
°C and lyophilized (yield: 23.16 %, w/w). The 
lyophilized powder was dissolved in 10 % 
dimethyl sulfoxide (DMSO; Sigma, St. Louis, 
MO) and then filtered through a 0.22 μm syringe 
filter and stored as stock until use. 
 
Isolation and culture of rat HSCs 
 
Specific pathogen-free male Wistar rats were 
purchased from Orient Bio (Seoul, Korea). The 
animal experimental protocol was approved by 
the Committee of Laboratory Animals according 
to institutional guidelines of Konkuk University, 
Korea. Animals were housed in conventional 
cages under control conditions of temperature 
(23 ± 3°C) and relative humidity (50 ± 20 %), 
artificial light (12:12-h light: dark cycle, lights on 
at 0700)  with free access to water and feed ad 
libitum prior to experiments. HSCs were isolated 
by in situ perfusion of livers from rats with 
collagenase and pronase, followed by differential 
centrifugation using Nycodenz (Histodenz™, 
Sigma, USA) density gradients as previously 
described [12]. HSCs were cultured in 
Dulbecco’s modified essential medium (DMEM, 
GIBCO®, USA) supplemented with 10 % fetal 
bovine serum (FBS, GIBCO®, USA) and 5 % 
antibiotics in a humidified air containing 5 % CO2 
at 37 °C. Growth medium was changed on a 
daily basis for the first two days in culture, then 
every second day thereafter. Experiments 
described in this study were performed using 
cells between days 2 and 7 in culture.  
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Cell viability assay 
 
Cell viability assays were evaluated by the 3-(4, 
5-dimethylthiazol-2yl)-2, 5-diphenyl-2H-
tetrazolium bromide (MTT) method. In a 96-well 
microplate, Chang cells (7 × 103 cells/well) were 
cultivated in DMEM medium supplemented as 
described previously [13].   Sample material was 
evaluated at various concentrations for 24 h at 
37 oC in an atmosphere of 5% CO2 and 95 % 
humidity. The cells were then incubated with 
MTT (5 mL; Sigma, USA) for 4 h, and the 
reaction was interrupted by addition of dimethyl 
sulphoxide (DMSO, Sigma, USA). An ELISA 
reader was used to obtain the results at 540 nm. 
The viabilities of the control cells were used as 
the control values at 100 %. All assays were 
performed in triplicate. 
 
Reverse transcription-polymerase chain 
reaction (RT-PCR) 
 
For RT-PCR, total RNA (1 μg) was reverse-
transcribed using Moloney murine leukemia virus 
reverse transcriptase Super-ScriptII and an oligo 
dT primer (Invitrogen, USA) at 42 °C for 1 h. 
cDNA (1 μL) was amplified using specific primers 
as appropriate. Primer sets were as follows; 
COL1A2; forward: 5'-GCT GAG GGC AAC AGC 
AGA TTC-3', reverse:5'- G A T G T C C A G A G 
G T G C A A T G T C A A -3'; TGF-β1; forward: 
5'- C T G T C C A A A C T A A G G C T C G C -
3', reverse: 5'- A C T G A A G C G A A A G C C 
C T G T A -3'; PDGF forward: 5'- C T G C C A C 
A G C A T G A T G A G G A T T G A T -3', 
reverse: 5'- G C C  A G G A T G G C T G A G A 
T C A C C A C -3'; α-SMA forward: 5'- G G T G C 
T G T C T C T C T A T G C C T C T G G A -3', 
reverse: 5'- C C C A T C A G G C A A C T C G A 
T A C T C T T C -3'; GAPDH; forward: 5'- G G C 
A C A G T C A A G G C T G A G A A T G -3', 
reverse: 5'- A T G G T G G T G A A G A C G C C 
A G T A -3'. GAPDH was used to verify that 
equal amounts of RNA were used for RT-PCR 
amplification from different experimental 
conditions. Products were electrophoresed on a 
1.5 % agarose gel and visualized by staining with 
ethidium bromide. 
 
Western blot analysis 
 
Cells were lysed in protein extract buffer (30 
mM/L of Tris-hydrochloride at pH 8.0, 10-mM/L of 
edetic acid, 1 % Triton X-100, 100 mM of sodium 
chloride, and 2 mM of phenylmethylsulfonyl 
fluoride), and then centrifuged for 1 min at 
14,000 rpm. The proteins were separated by 10 
% sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis and transferred to a 
nitrocellulose membrane (Bio-Rad, USA). The 
membranes were then blocked for 1 h in Tris-
buffered saline and Tween-20 buffer, consisting 
of 20 mM of Tris-hydrochloride (pH 7.6), 135 mM 
of sodium chloride, 1 % Tween-20, and 5 % non-
fat dry milk, and incubated at 4 °C for 8 h with 
monoclonal Smad antibody and polyclonal 
COL1A2 antibody. After incubation, the 
membrane was washed three times for 5 min in 
Tris-Buffered saline and Tween-20 buffer, and 
then treated with peroxidase-conjugated anti–
rabbit IgG antibody (Vector Laboratories, 
Burlingame, CA) at a dilution of 1:1000 for 2 h at 
room temperature. The membrane was washed, 
and substrate was added from an enhanced 
chemiluminescence reagent kit (Du Pont, 
Boston, MA, USA) and detection is LAS-3000. As 
an internal control, β-actin expression was 





Data are presented as mean ± standard error of 
mean (n = 6). Differences between two groups 
were analyzed for statistical significance using 
Student’s t-test. In all experiments, p < 0.05 was 




Effect of RJE on Chang cell viability and 
morphology of HSCs  
 
As shown in Fig. 1, RJE treated at various 
concentrations (100, 300 and 500 µg/mL) did not 
show significant changes in the overall cell 
viability nor produced toxicity to Chang cells. 
However, treatment with 1000 µg/mL of RJS 
showed significant toxicity in Chang cells (p < 
0.001). Therefore, further experiments were 
carried using 500 µg/ml of RJE as it was safe 
concentration (Fig. 1). 
 
Effect of RJE on cell morphology in culture-
activated HSCs 
 
Treatment with RJE (500 μg/mL) for 24 h, on 8 
day-cultured primary HSCs showed shrinking 
morphology (Fig. 3). Treatment with RJE 
decreased the number of viable HSCs, and the 
stretched fiber was decreased when compared to 
the untreated activated HSCs in 24 h at 500 
μg/mL (Fig 3B). 
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Fig 1: Cell viability of RJE in Chang liver cells. Data are presented as mean ± SEM (n = 6). NS = not significant 
when compared with control groups; *p < 0.05, when compared with control group; RJE = Rhus javanica extract. 
   
 
Fig 2: Morphology of isolated HSCs and activated HSCs. HSC was isolated for 1 day (A), 2 days (B), 4 days (C), 
6 days (D) and 8 days (E).  Microscope magnification = x100. Arrows indicate HSCs. HSCs: Hepatic stellate cells 
 
 
Fig 3: Effect of RJE on the activated HSCs morphologies. The cells were exposed to the indicated concentration 
(500 µg/mL) of RJE for 24 h. Control cells were supplemented with same amount of vehicle medium. A = 
activated HSCs and B = after 24 h treatment with RJE (B). Microscope magnification was x100. Arrows indicate 
HSCs; RJE = Rhus javanica extract; HSCs: Hepatic stellate cells 
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Effect of RJE on COL1A2, α-SMA, TGF-β and 
PDGF mRNA expression in activated HSCs  
 
As shown in Fig. 4A, in the presence of 500 
μg/mL of RJE the mRNA expressional levels of 
COL1A2, TGF-β and α-SMA were suppressed in 
activated HSC. However, RJE did not influence 
the PDGF expression in activated HSCs. Band 
intensities of related genes such as COL1A2, 
TGF-β and α-SMA revealed a significant 
decrease (p < 0.05) when treated with RJE at 
500 µg/mL concentration suggesting that RJE 
inhibited the fibrosis production inhibited the 
fibrosis mediators in activated HSCs (Fig. 4B). 
 
Effect of RJE on the protein expressional 
levels of COL1A2 and Smad 
 
Treatment with RJE (500 µg/mL) suppressed the 
expressional levels of COL1A2 and Smad 




Fig 4: Effect of RJE on collagen expression of fibrosis-related genes and cytokines in activated HSCs. A = Cells 
were pretreated with RJE on activated HSCs for 24 h. B = Band intensities of relative genes such as COL1A2, 
TGF-β, α-SMA and PDGF respectively. Data are presented as mean ± SEM (n = 3); differences between two 
groups were analyzed for statistical significance using the Student’s t-test; *p < 0.05 when compared with 
COL1A2, TGF-β and α-SMA genes respectively in untreated groups; NS = not significant when compared to 
PDGF gene expression in untreated group; RJE = Rhus javanica extract; HSCs: Hepatic stellate cells; COL1A2 = 
Collagen, type I, alpha 2; TGF-β = Transforming growth factor-beta; PDGF = Platelet-derived growth factor; α-
SMA = Alpha-smooth muscle actin and GAPDH = Glyceraldehyde 3-phosphate dehydrogenase 
 
 
Fig 5: Effect of RJE on COL1A2 and Smad protein expressional levels in activated HSCs. A = cells were 
pretreated with RJE to activated HSCs for 24 h. B = band intensity of relative genes (COL1A2 and Smad, 
respectively). Data are presented as mean ± SEM (n = 3). Differences between two groups were analyzed for 
statistical significance using the Student’s t test; *p < 0.05 when compared with COL1A2 and Smad, respectively, 
in untreated groups. RJE = Rhus javanica extract; HSCs: Hepatic stellate cells; COL1A2 = Collagen, type I, alpha 
2 
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Currently, antifibrotic therapeutic strategies 
include inhibition of HSC proliferation or 
stimulation of HSC apoptosis, down-regulation of 
collagen production or promotion of its 
degradation, administration of cytokines, and 
infusion of mesenchymal stem cells. Also, 
upregulation of collagen synthesis during 
activation is among the most striking molecular 
responses of HSCs to injury and is mediated by 
both transcriptional and post-transcriptional 
mechanisms. Transcriptional activation of type I 
collagen has been extensively characterized [14]. 
For that reason, HSCs plays a key role in hepatic 
fibrogenesis. Therefore HSC activation model 
can serve as a useful tool for screening liver 
fibrosis inhibition activities. Recently, several 
herbal and natural products including R. javanica 
have been used worldwide for the treatment of 
some liver diseases based on the plants’ 
antioxidant defense mechanisms [10].  
 
In the present investigation, RJE up to 500 
μg/mL did not exhibit any signs of cytotoxicity to 
HSCs. During the process of hepatic fibrosis 
HSCs become activated with characteristic cell 
proliferation and migration, production of 
collagen and other ECM molecules such as 
elastin, microfibrillar proteins, proteoglycans 
including hyaluronan, and noncollagenous 
glycoproteins, finally transforming into 
myofibroblasts. To obtain minimum 
contamination from other non-parenchymal cells, 
we used collagenase and pronase perfusion 
method for the isolation of hepatic stellate cells. 
This technique also allowed the simultaneous 
isolation of hepatocytes and HSCs. 
 
It has been well known that HSCs are important 
anti-fibrotic targets and are considered as the 
main ECM producing cells in the injured liver 
[15]. Following chronic injury, HSCs activate or 
trans-differentiate into myofibroblast-like cells 
and accumulate increased ECM proteins. 
Hepatic fibrosis is associated with increased 
levels of TGF-β which initially recruit 
inflammatory cells and fibroblasts into an area of 
injury and then stimulate these cells to produce 
cytokines and ECM, because TGF-β not only 
enhances ECM synthesis but also inhibits ECM 
degradation [16,17]. HSCs up-regulate gene 
expression of ECM components, matrix-
degrading enzymes and their respective 
inhibitors, resulting in matrix remodeling and 
accumulation at sites with abundant activated 
HSCs [2,18].  
 
PDGF and TGF-β are the two best-characterized 
cytokines in stellate cell activation. A large 
number of studies identify PDGF as the main 
mediator for proliferation and TGF-β as the most 
important cytokine stimulating fibrogenesis in 
stellate cells [12,19]. The fibrosis pathway 
includes a signaling crosstalk following TGF-β 
binding to the receptor. Signal pathways 
potentially important here include the MAP 
kinase JNK. This would synergize with the Smad 
signaling pathway and decrease the activation of 
downstream TGF-β-dependent genes. 
Alternatively, NO could enhance the proteasomal 
degradation of Smad [20].  In the current study, 
down-regulation of fibrosis mediators by RJE 
was found to be due to the inhibition of TGF-β1 
pathway. Further, to verify the inhibitory 
mechanism of RJE on fibrosis we evaluated the 
phosphorylation of Smad two major TGF-β1 
pathway signaling proteins. The inhibitory action 
of RJE was mediated by prevention TGF-β1 
activation and by inhibition of Smad expression, 





The findings indicate that RJE influenced the 
morphology of cultured/activated HSCs and 
inhibited fibrosis production enhanced by TGF-β 
gene. RJE also inhibits expression of α-SMA 
gene and collagen gene, and causes a marked 
blockage of Smad expression. Down-regulation 
of fibrosis mediators by RJE is due to inhibition of 
TGF-β signaling pathway. This is the first report 
showing the beneficial effects of R. javanica as 
an anti-fibrotic agent, suggesting that it is a 
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